Chloroprocaine
Clorotekal
- Dosage form
- Tablet
- Available strengths
- 50 mg/5 mL (10 mg/mL)
- Drug class
- Ester-type local anesthetic
- Common brand
- Clorotekal
Clinical overview. Chloroprocaine (Clorotekal) is a rapid-onset, ester-type local anesthetic given as a single spinal (intrathecal) injection to numb the lower body for surgical procedures lasting up to 40 minutes. It is administered only by trained healthcare professionals in a setting equipped to manage anesthesia-related emergencies. Patients are closely monitored for low blood pressure, slow heart rate, and neurological symptoms during and after the procedure.
Indication
Common therapeutic uses
- Chloroprocaine (Clorotekal) is used to induce spinal anesthesia by intrathecal injection in adults undergoing surgical procedures lasting no longer than 40 minutes.
- It is administered only by clinicians experienced in intrathecal anesthesia, in a setting equipped to manage anesthesia-related emergencies.
Pregnancy
Risk assessment and monitoring considerations
- Chloroprocaine is not recommended during pregnancy and should be used cautiously in women of childbearing potential not using contraception.
- Local anesthetics rapidly cross the placenta and can affect the mother, fetus, and newborn to varying degrees, so use during pregnancy should only be considered if the expected benefit to the mother outweighs the potential risk to the fetus.
- Spinal anesthesia may alter the forces of labour through effects on uterine contractility or the mother's ability to push.
Breastfeeding
Infant exposure considerations
- It is not known whether chloroprocaine or its metabolites pass into breast milk, so the decision to breastfeed or to receive chloroprocaine should weigh the benefits of breastfeeding against the need for the anesthetic.
Geriatrics
Dosing and tolerability considerations
- Patients over 65, especially those with high blood pressure, may be at increased risk of low blood pressure during spinal anesthesia with chloroprocaine.
- Elderly patients more often have reduced liver, kidney, or heart function, or take other medications, any of which may affect their response to chloroprocaine, so caution is advised.
Pediatrics
Use in children and adolescents
- The safety and efficacy of chloroprocaine intrathecal injection have not been established in patients under 18, and Health Canada has not authorized its use in this age group.
Dosage & Administration
Practical dosing and administration
- For adults of average height and weight, about 70 kg, the recommended dose to achieve an effective spinal block to the T10 level is 50 mg (5 mL) as a single intrathecal injection.
- The maximum recommended dose is 50 mg (5 mL); doses above this have not been adequately tested for safety or effectiveness.
- A lower dose of 40 mg (4 mL) can be used for a more limited sensory block, though its duration of action, about 80 minutes, is shorter than the 50 mg dose, about 100 minutes.
- The dose should be reduced in patients with a compromised general condition or with disorders such as vascular disease, arteriosclerosis, or diabetic neuropathy.
- The entire dose is injected slowly into the L2/L3, L3/L4, or L4/L5 intervertebral space after confirming correct needle placement by aspirating cerebrospinal fluid.
- Chloroprocaine is not approved for epidural administration, continuous spinal catheter use, or intravenous regional anesthesia.
- Each ampoule is for single use only; any unused portion must be discarded, and the product must not be mixed or diluted with other drugs.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Early signs of local anesthetic toxicity include numbness or tingling around the mouth, a numb tongue, a dazed feeling, ringing in the ears, and visual disturbances.
- These early signs can progress to muscle twitching and then a generalized seizure, usually lasting seconds to a few minutes.
- Seizure activity can lower blood oxygen and raise blood carbon dioxide levels, and in severe cases breathing may stop.
- High systemic drug levels can cause cardiovascular toxicity, including slow heart rate, low blood pressure, abnormal heart rhythms, or cardiac arrest.
- Treatment involves immediately stopping the chloroprocaine, securing the airway and giving oxygen (with assisted ventilation if needed), and stabilizing blood pressure and circulation.
- Seizures that do not stop on their own within 15 to 20 seconds are treated with an intravenous anticonvulsant.
- In patients with a genetic deficiency of the enzyme that breaks down chloroprocaine (plasma cholinesterase), intravenous lipid emulsion may be given as treatment.
Common side effects
Frequently reported tolerability concerns
- Drowsiness may occur.
- Headache may occur.
- Nausea may occur.
- Vomiting may occur.
- Diarrhea may occur.
- Pain at the injection site may occur.
- Restlessness may occur.
- Muscle spasm may occur.
- Muscle weakness may occur.
- Light-headedness or a feeling of being about to faint may occur.
- Low blood pressure (hypotension) commonly occurs and may cause dizziness, fainting, blurred vision, nausea, or fatigue, especially on standing.
- Slow heart rate (bradycardia) commonly occurs.
- Anxiety, sometimes with sweating, nausea, shortness of breath, or palpitations, may occur.
- Post-lumbar puncture syndrome, with headache, nausea, vomiting, dizziness, or back pain, may occur after the procedure.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Severe drops in blood pressure and heart rate can occur, and in rare cases may progress to cardiac arrest.
- Loss of consciousness may occur.
- Numbness, tingling, loss of sensation, or motor weakness may occur and can persist or become permanent.
- Paralysis has been reported.
- Cauda equina syndrome, involving pressure and swelling of the nerves at the base of the spinal cord, may cause burning pain, back or leg pain, and loss of bladder, bowel, or sexual function.
- Severe allergic reactions, including anaphylaxis, have been reported and can be life-threatening or fatal.
- Irreversible breakdown of joint cartilage (chondrolysis) has been reported, primarily with unapproved intra-articular use of local anesthetics.
- Respiratory depression, including slow or shallow breathing, may occur and can progress to respiratory arrest.
- Hearing problems, including ringing in the ears or a sense of spinning, may occur.
- Vision problems, including blurred or double vision or light sensitivity, may occur.
- Seizures have been reported.
- Seek immediate medical help for chest pain, severe shortness of breath, loss of bladder or bowel control, signs of a severe allergic reaction, or a very slow or irregular heartbeat.
Use with caution
Situations requiring closer assessment
- Use with caution in patients with impaired cardiovascular function, including partial or total heart block, since local anesthetics can further suppress heart conduction.
- Use with caution in patients with advanced liver disease, since ester-type local anesthetics like chloroprocaine are broken down by an enzyme produced in the liver.
- Use with caution in patients with impaired kidney function, since chloroprocaine and its breakdown products are substantially cleared by the kidneys.
- Use with caution in patients with underlying neuromuscular disorders, weighing the risks and benefits before treatment.
- Use with caution in patients with a genetic deficiency of plasma cholinesterase, since this can prolong the drug's activity and increase the risk of toxicity.
- Advise patients to use caution when driving or operating machinery after receiving chloroprocaine, until they know how they are affected.
- Continuous monitoring of blood pressure, heart rhythm, breathing, and level of consciousness is required during and after chloroprocaine administration.
- Do not puncture the skin for injection if there are signs of infection or inflammation at the site.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients hypersensitive to chloroprocaine, other medicines in the PABA (para-aminobenzoic acid) ester group, or any ingredient in the formulation.
- Contraindicated in patients with general or specific contraindications to spinal anesthesia, such as decompensated heart failure or hypovolemic shock.
- Contraindicated for intravenous regional anesthesia.
- Contraindicated in patients with serious cardiac conduction problems.
- Contraindicated in patients with severe anemia.
- Contraindicated in patients taking anticoagulant (blood-thinning) medication or with a congenital or acquired bleeding disorder.
- Contraindicated in patients with septicemia or a local infection at the intended injection site.
Drug interactions
Clinically relevant combinations
- Concurrent use of vasopressor drugs or ergot-type oxytocic drugs, such as ergotamine or dihydroergotamine, with chloroprocaine may cause severe, persistent high blood pressure or stroke.
- Chloroprocaine's breakdown product inhibits the action of sulfonamide antibiotics, so chloroprocaine should be avoided in patients being treated with a sulfonamide drug.
- Combining chloroprocaine with class III antiarrhythmic drugs, such as amiodarone, requires careful cardiac monitoring, since interactions have not been studied.
- Combining chloroprocaine with other local anesthetics may have additive effects on the heart and central nervous system, increasing toxicity risk.
- Concurrent use with chloroform, halothane, cyclopropane, trichloroethylene, or related anesthetic agents may increase the risk of serious cardiac arrhythmias.
- Chloroprocaine is contraindicated with anticoagulant medications because of an increased bleeding risk at the injection site.
Food interactions
Meal-related administration
- No food interactions have been established for chloroprocaine, consistent with its use as a single-dose injectable anesthetic administered in a clinical setting.
Time of administration
Practical scheduling
- Chloroprocaine is given as a single intrathecal injection immediately before a surgical procedure by a trained healthcare professional; it is not a medication patients take on their own schedule or at home.
- The onset of anesthesia is rapid, typically within 6 to 12 minutes of injection.
Storage
Product handling
- Store at room temperature, 15°C to 30°C; do not refrigerate, freeze, heat, or autoclave, and keep the ampoule in its carton to protect it from light until ready to use.
Patient take-away
Key counselling points for a quick closing summary
- Clorotekal is a fast-acting spinal anesthetic given only by trained healthcare professionals in a hospital setting; expect close monitoring of blood pressure, heart rate, and breathing during and after your procedure, and report any lasting numbness, weakness, or back or leg pain promptly, as these can signal a serious nerve-related complication.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.